Table 1. Clinical characteristics of the "tumor tissue" patient cohort.*.
| pat. # | category | age [years) | sex | tumor site | stage (AJCC/TNM) | KRAS status | no. of previous treatments | treatment | treatment duration [months] | best response |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | panitumumab group | 36 | rn | rectum | lit | wt | 1 | Foil oxiPan | 3 | PD |
| 2 | 50 | m | colon | IV | wt | 0 | Folt ox/Pan | 3 | PR | |
| 3 | 70 | m | rectum | IV | wt | 1 | Foil ki/Pan | 8 | PR | |
| 4 | 59 | m | colon | IV | wt | 3 | FothriPan | 3 | PD | |
| 5 | 46 | f | colon | IV | wt | 3 | 5•FurFsvPan | 6 | SD | |
| 6 | 62 | m | CCC | IV | wt | 0 | Ce/GemPan | 6 | SD | |
| 7 | 75 | rn | CCC | IV | wt | 0 | Gs/Geer/Pan | 6 | SD | |
| 8 | 62 | m | rectum | IV | wt | 1 | Follii/Pan | 6 | PR | |
| 9 | cetuximab group | 76 | in | rectum | IV | wt | 1 | FollwieCet | 3 | SD |
| 10 | 70 | f | colon | IV | wt | 1 | Fortin/eat | 6 | SD | |
| 11 | 68 | m | rectum | 1118 | wt | 1 | Met/SM | 6 | PR | |
| 12 | 58 | m | rectum | IV | wt | 1 | InCet | 3 | PR | |
| 13 | 59 | rn | rectum | IV | wt | 2 | Folf ii/Cet | 3 | PR | |
| 14 | 43 | rn | rectum | IV | wt | 1 | FothriCet | 6 | SD | |
| 15 | 47 | f | CUP | IV | wt | 0 | Cato/Fact/Cet | 4 | PR | |
| 16 | 72 | in | CUP | IV | wt | 0 | Carbo/Fact/Cet | 4 | PD | |
| 17 | control group | 74 | f | rectum | IV | mut. | 0 | 5•1.1/FA/Bev | 3 | SD |
| 18 | 53 | m | colon | IV | wt | 0 | XeloxBev | 3 | PR | |
| 19 | 58 | in | rectum | IV | mut. | 0 | FollowyBev | 4 | PR | |
| 20 | 65 | rn | colon | IV | mut. | 0 | Xelox/Bev. Xelox | 2/6 | PD | |
| 21 | 58 | m | colon | IV | wt | 0 | Fotrousev | 2 | SD |
*
Stage refers to the stage at diagnosis; treatment, treatment duration and response refers to the indicated antibody-containing treatment or the control treatment. respectively; KRAS status was established by routine clinical testing at diagnosis covering exon 2 and 3 mutations, response was evaluated according to recist criteria. Bev= Bewizumab, Carbo = carboplatinum, Cet = Cetuximab. Cis = cisplatinum, FA = blinic acid, Gem = gemcitabine, Iri = irinotecan, Pacli = paclitaxel, Pan = Panitumumab, SM = study medication. Xelox = Yeloda + oxaliplatinum, 5•FU = 5•ffuorouracile: CCC = cholangiocellular cancer. CUP = cancer of unknown primary: CR = complete remission, PR = partial remission, SD = stable disease. PD = progressive disease